BioCentury This Week

Ep. 350 - Oral SERD Spotlight. Plus: Setbacks at FDA

Ep. 349 - Start-up Spotlight, Compounding Wegovy & Neuropysch

Ep. 348 - Biotech's 2026 Catalysts. Plus: China's New Orphan Rules

Ep. 347 - Speeding China's Innovation. Plus: Neuro Catalysts and Newcos

Ep. 346 - 2026 Public Markets Preview

Ep. 345 - TAC to the Future. Plus: GSK Deal, MFN

Ep. 344 - JPM Momentum and Asia’s Hotbeds of Innovation

Ep. 343 - JPM Deals, Policy Outlook, Approval Trends

The podcast opens with a discussion on the JP Morgan conference and potential M&A activities, including rumors around Abivax and RevMed. It shifts to recent deal activity, such as AbbVie's acquisition of a Remagen bi-specific asset, with an analysis of its value relative to similar deals. The conversation explores new ...

Ep. 342 - 2026 Biotech Kickoff

Ep. 341 - BioCentury's '25-'26 Picks. Plus: BioMarin & Biotech ICYMI

Ep. 340 - Obesity Data, Kymera & FDA Survey Results

Ep. 339 - Biotech M&A, In Vivo CAR Ts & FDA Tumult

Ep. 338 - Semaglutide’s Alzheimer’s Miss. Plus: Vaccine Policy, C&GT Funding

Ep. 337 - FDA’s Moving Goalposts & China’s Innovation Arc

Ep. 336 - Cautious Optimism and M&A Momentum

Ep. 335 - Neurology's Coming Inflection Point

Ep. 334 - Pazdur’s New FDA Role, SITC & China RNAi

Ep. 333 - Is This Korea’s Biotech Moment?

Ep. 332 - Obesity in Focus. Plus: What’s Next for FDA

Ep. 331 - Metsera M&A Melee & Tidmarsh Ouster